Economics at your fingertips  

Validation of surrogate end points in multiple randomized clinical trials with failure time end points

Tomasz Burzykowski, Geert Molenberghs, Marc Buyse, Helena Geys and Didier Renard

Journal of the Royal Statistical Society Series C, 2001, vol. 50, issue 4, 405-422

Abstract: Before a surrogate end point can replace a final (true) end point in the evaluation of an experimental treatment, it must be formally ‘validated’. The validation will typically require large numbers of observations. It is therefore useful to consider situations in which data are available from several randomized experiments. For two normally distributed end points Buyse and co‐workers suggested a new definition of validity in terms of the quality of both trial level and individual level associations between the surrogate and true end points. This paper extends this approach to the important case of two failure time end points, using bivariate survival modelling. The method is illustrated by using two actual sets of data from cancer clinical trials.

Date: 2001
References: Add references at CitEc
Citations: View citations in EconPapers (13) Track citations by RSS feed

Downloads: (external link)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link:

Ordering information: This journal article can be ordered from
http://ordering.onli ... 1111/(ISSN)1467-9876

Access Statistics for this article

Journal of the Royal Statistical Society Series C is currently edited by R. Chandler and P. W. F. Smith

More articles in Journal of the Royal Statistical Society Series C from Royal Statistical Society Contact information at EDIRC.
Bibliographic data for series maintained by Wiley Content Delivery ().

Page updated 2019-08-08
Handle: RePEc:bla:jorssc:v:50:y:2001:i:4:p:405-422